ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ceftobiprole medocaril

Also written as “Ceftobiprole medocaril”, “Ceftobiprole medocaril sodium” and “Ceftobiprole Medocaril”.

Its studies are mostly in Community-Acquired Pneumonia · Staphylococcal Skin Infections · Endocarditis, Bacterial · Staphylococcal Infections · Neonatal Sepsis, led by 2 companies.

Drug pageCeftobiprole medocaril: every studyAll 11 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 13, 200511 company-led studies, 1 open or runningNext primary completion: Oct 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Basilea Pharmaceuticaits history only100 open or runningphase 3since Sep 13, 2005Sep 13, 2005none ahead
ISTx11 open or runningphase 3since Oct 19, 2026Oct 19, 2026Oct 31, 2028phase 3 · NCT07929493

Also a collaborator on its studies: Innoviva Specialty Therapeutics.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of ISTx only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 19, 2026First study: phase 3 study in Endocarditis, BacterialFirst studyNCT07929493 · 60 planned

Ahead

  1. Oct 31, 2028Primary completion: phase 3 study in Endocarditis, BacterialNCT07929493

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Penicillin-binding protein 1 inhibitor; Penicillin-binding protein 2 inhibitor; Penicillin-binding protein inhibitor; Penicillin-binding protein 4 inhibitor”ChEMBL 37, by rule

Studies

The one study ISTx leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07929493Endocarditis, Bacterial3Not yet recruitingOct 31, 202860

How it is read

Names in the registry

  • “Ceftobiprole medocaril”, 5 entries
  • “ceftobiprole medocaril”, 4 entries
  • “Ceftobiprole medocaril sodium”, 1 entry
  • “Ceftobiprole Medocaril”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.